Last edition
News about "Senhwa Biosciences"
Senhwa Biosciences Secures US FDA Nod to Advance Pidnarulex Trial for MYC-Driven B-Cell Lymphoma
Senhwa Biosciences has received FDA clearance to begin a Phase 1b/2 trial of its novel MYC-targeting drug candidate Pidnarulex (CX-5461) in patients with B-cell lymphoma, marking a potential breakthrough in precision oncology.
Senhwa Biosciences | 06/09/2025 | By Mrinmoy Dey | 149
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members